IP Library Patent Application 12822060
Patent Application
App. No. 12/822,060

METHODS OF INCREASING NEURONAL DIFFERENTIATION USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/822,060
Abstract

Methods are provided for increasing neuronal differentiation of neuronal stem cells using antibodies that bind lysophosphatidic acid (LPA). Particularly preferred antibodies to LPA are monoclonal antibodies, including humanized monoclonal antibodies to LPA. Such antibodies, and derivatives and variants thereof, can be used in increasing neuronal differentiation, and in treatment and/or prevention of injuries, diseases, or conditions associated with insufficient neuronal differentiation and/or with elevated LPA levels in neural tissues.

Claims (14)

1 . A method for increasing neuronal differentiation of neural stem cells, comprising delivering an antibody, or a fragment, variant, or derivative thereof, that binds lysophosphatidic acid, to an environment that also comprises neural stem cells so that levels of lysophosphatidic acid in the environment and/or in said cells are decreased and neuronal differentiation is increased.

2 . A method according to claim 1 wherein an increase in neuronal differentiation of said neural stem cells is determined by an increase in neuron formation.

3 . A method according to claim 1 wherein an increase in neuronal differentiation of said neural stem cells is determined by a decrease in gliogenesis.

4 . A method according to claim 1 wherein the increase in neuronal differentiation or the decrease in gliogenesis occurs in vivo.

5 . A method according to claim 1 wherein the increase in neuronal differentiation or the decrease in gliogenesis occurs in vitro.

6 . A method according to claim 1 wherein the increase in neuronal differentiation or the decrease in gliogenesis occurs in neurospheres.

7 . A method according to claim 1 wherein the antibody that binds lysophosphatidic acid is a monoclonal antibody, or a fragment, variant, or derivative thereof, that binds lysophosphatidic acid.

8 . A method according to claim 7 wherein the monoclonal antibody is a humanized monoclonal antibody, or a fragment, variant, or derivative thereof.

9 . A method for treating a disease, condition, or injury of the nervous system in an animal, preferably a human, wherein said condition is associated with undesirably high levels of lysophosphatidic acid, said method comprising treating said animal with an antibody that binds lysophosphatidic acid, so that levels of said lysophosphatidic acid in the nervous system of the animal are reduced.

10 . A method according to claim 9 wherein said disease or condition is selected from the group consisting of traumatic brain injury, stroke, brain or spinal cord hemorrhage, spinal cord injury, cancer of the central nervous system, and a neurodegenerative disease.

11 . A method according to claim 10 wherein the neurodegenerative disease is selected from the group consisting of Parkinson's disease, Alzheimer's disease, and Huntington's disease.

12 . A method for treating a disease, condition, or injury of the nervous system in an animal, preferably a human, wherein said condition is associated with insufficient neuronal differentiation, said method comprising treating said animal with an antibody that binds lysophosphatidic acid, so that levels of said lysophosphatidic acid in the nervous system of the animal are reduced and neuronal differentiation is increased.

13 . A method according to claim 12 wherein said disease or condition is selected from the group consisting of traumatic brain injury, stroke, brain or spinal cord hemorrhage, spinal cord injury, cancer of the central nervous system, and a neurodegenerative disease.

14 . A method according to claim 13 wherein the neurodegenerative disease is selected from the group consisting of Parkinson's disease, Alzheimer's disease, and Huntington's disease.

Assignments (4)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Mar 18, 2019
From: ATHYRIUM OPPORTUNITIES II ACQUISITION LP, AS ADMINISTRATIVE AGENT
To: APOLLO ENDOSURGERY, INC.
Reel/Frame 048622/0358 →
CHANGE OF NAME Recorded Mar 27, 2017
From: LPATH, INC.
To: APOLLO ENDOSURGERY, INC.
Reel/Frame 042097/0896 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 30, 2016
From: APOLLO ENDOSURGERY, INC.
To: ATHYRIUM OPPORTUNITIES II ACQUISITION LP, AS ADMINISTRATIVE AGENT
Reel/Frame 041224/0766 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2010
From: PEBAY, ALICE MARIE; TURNLEY, ANN MAREE
To: LPATH, INC.
Reel/Frame 025472/0762 →